United States of America
Jennifer Lockridge, Ph.D., is VP of Program Development at Dicerna Pharmaceuticals and has twenty years of experience in the development of oligonucleotide therapeutics. Prior to joining Dicerna, Dr. Lockridge spent nine years consulting with multiple biotech and large pharmaceutical companies to provide direction and support for early development stage oligonucleotide programs as well as pharmacology and pharmacokinetics expertise. From 1996 to 2007, she was employed at Sirna Therapeutics, Inc. (formerly Ribozyme Pharmaceuticals, Inc.). As Director of Project Management at Sirna, she managed and was involved with all aspects of siRNA and ribozyme development programs. Dr. Lockridge received her Ph.D. in pharmacology at the Oregon Health Sciences University, Portland, Oregon and pursued postdoctoral training at the FDA’s National Center for Toxicological Research, Jefferson, Arkansas.
Her research interest in Business and Management